Benjamin T. Dake - 31 Jul 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
31 Jul 2024
Net transactions value
+$22,552
Form type
4
Filing time
02 Aug 2024, 18:00:22 UTC
Previous filing
19 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $19,930 +11,454 +887% $1.74 12,745 31 Jul 2024 Direct
transaction AVTE Common Stock Options Exercise $2,622 +1,507 +12% $1.74 14,252 01 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -906 -100% $0.000000* 0 31 Jul 2024 Common Stock 906 $1.74 Direct F1
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -10,548 -87% $0.000000 1,507 31 Jul 2024 Common Stock 10,548 $1.74 Direct F2
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -1,507 -100% $0.000000* 0 01 Aug 2024 Common Stock 1,507 $1.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2 A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary